Literature DB >> 1651586

Characterization of the Sendai virus V protein with an anti-peptide antiserum.

J Curran1, M de Melo, S Moyer, D Kolakofsky.   

Abstract

The Sendai virus V protein, which is a fusion of the P and V ORFs of the P gene, was characterized with antisera to a portion of the V ORF and compared to the P protein. The only property found in common with P is that V is also highly phosphorylated, and this is so even when these proteins are expressed independently of the other viral proteins. Otherwise, V was not found in virions, was not strongly associated with viral nucleocapsids like P, and anti-V had no effect on viral RNA synthesis in vitro under conditions where anti-P was highly inhibitory. The available evidence suggests that V may play a role in RNA synthesis, but it is not an essential one like that of the P protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651586      PMCID: PMC7130646          DOI: 10.1016/0042-6822(91)90827-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  52 in total

1.  Editing of the Sendai virus P/C mRNA by G insertion occurs during mRNA synthesis via a virus-encoded activity.

Authors:  S Vidal; J Curran; D Kolakofsky
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

2.  Two noncontiguous regions of Sendai virus P protein combine to form a single nucleocapsid binding domain.

Authors:  K W Ryan; E M Morgan; A Portner
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

3.  Mapping of monoclonal antibodies to the Sendai virus P protein and the location of its phosphates.

Authors:  S Vidal; J Curran; C Orvell; D Kolakofsky
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

4.  Sendai virus contains overlapping genes expressed from a single mRNA.

Authors:  C Giorgi; B M Blumberg; D Kolakofsky
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

5.  Molecular cloning and sequence analysis of the human parainfluenza 3 virus mRNA encoding the P and C proteins.

Authors:  M S Galinski; M A Mink; D M Lambert; S L Wechsler; M W Pons
Journal:  Virology       Date:  1986-11       Impact factor: 3.616

6.  Measles virus editing provides an additional cysteine-rich protein.

Authors:  R Cattaneo; K Kaelin; K Baczko; M A Billeter
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

7.  Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex.

Authors:  M Hamaguchi; T Yoshida; K Nishikawa; H Naruse; Y Nagai
Journal:  Virology       Date:  1983-07-15       Impact factor: 3.616

8.  Molecular cloning and nucleotide sequence of P, M and F genes of Newcastle disease virus avirulent strain D26.

Authors:  H Sato; M Oh-hira; N Ishida; Y Imamura; S Hattori; M Kawakita
Journal:  Virus Res       Date:  1987-05       Impact factor: 3.303

9.  A stuttering model for paramyxovirus P mRNA editing.

Authors:  S Vidal; J Curran; D Kolakofsky
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

10.  Scanning independent ribosomal initiation of the Sendai virus Y proteins in vitro and in vivo.

Authors:  J Curran; D Kolakofsky
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  11 in total

1.  Involvement of the zinc-binding capacity of Sendai virus V protein in viral pathogenesis.

Authors:  C Huang; K Kiyotani; Y Fujii; N Fukuhara; A Kato; Y Nagai; T Yoshida; T Sakaguchi
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Authors:  Anne Schaap-Nutt; Caraline Higgins; Emerito Amaro-Carambot; Sheila M Nolan; Christopher D'Angelo; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

3.  The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis.

Authors:  A Kato; K Kiyotani; Y Sakai; T Yoshida; Y Nagai
Journal:  EMBO J       Date:  1997-02-03       Impact factor: 11.598

4.  Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis.

Authors:  A Kato; K Kiyotani; Y Sakai; T Yoshida; T Shioda; Y Nagai
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Rinderpest viruses lacking the C and V proteins show specific defects in growth and transcription of viral RNAs.

Authors:  M D Baron; T Barrett
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.

Authors:  Anne Schaap-Nutt; Christopher D'Angelo; Emerito Amaro-Carambot; Sheila M Nolan; Stephanie Davis; Shenelle-Marie Wise; Caraline Higgins; Konrad Bradley; Olivia Kim; Reina Mayor; Mario H Skiadopoulos; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  Virology       Date:  2010-07-27       Impact factor: 3.616

7.  Complete genome sequence and pathogenicity of two swine parainfluenzavirus 3 isolates from pigs in the United States.

Authors:  Dan Qiao; Bruce H Janke; Subbiah Elankumaran
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  The mumps virus V protein is unstable in virus infected cells.

Authors:  A Hu; S Schwartz; G Utter; C Orvell; J Kövamees; E Norrby
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  Inducible expression of the P, V, and NP genes of the paramyxovirus simian virus 5 in cell lines and an examination of NP-P and NP-V interactions.

Authors:  B Precious; D F Young; A Bermingham; R Fearns; M Ryan; R E Randall
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.

Authors:  Anne Schaap-Nutt; Christopher D'Angelo; Margaret A Scull; Emerito Amaro-Carambot; Machiko Nishio; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  Virology       Date:  2009-12-07       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.